TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ITOVEBI

INAVOLISIB Phosphoinositide 3-Kinase alpha Inhibitors
Oncology Approved 2024-10-10
1
Indication
--
Phase 3 Trials
1
Priority Reviews
1
Years on Market

Details

Status
Prescription
First Approved
2024-10-10
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: INAVOLISIB

ITOVEBI Approval History

Loading approval history...

What ITOVEBI Treats

1 indications

ITOVEBI is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Breast Cancer
Source: FDA Label

ITOVEBI Target & Pathway

Pro

Target

PI3K (Phosphoinositide 3-Kinase) Intracellular Kinase

A family of enzymes involved in cell growth, proliferation, and survival signaling. PI3K pathway activation is common in cancer. Inhibiting specific PI3K isoforms is effective in certain blood cancers and solid tumors.

Drugs Similar to ITOVEBI

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AFINITOR
EVEROLIMUS
1 shared
Novartis
Shared indications:
Breast Cancer
AFINITOR DISPERZ
EVEROLIMUS
1 shared
Novartis
Shared indications:
Breast Cancer
AN-SULFUR COLLOID
TECHNETIUM TC-99M SULFUR COLLOID KIT
1 shared
Sun Pharma
Shared indications:
Breast Cancer
ARIMIDEX
ANASTROZOLE
1 shared
ANI PHARMS
Shared indications:
Breast Cancer
AROMASIN
EXEMESTANE
1 shared
Pfizer
Shared indications:
Breast Cancer
AVGEMSI
GEMCITABINE HYDROCHLORIDE
1 shared
AVYXA HOLDINGS
Shared indications:
Breast Cancer
BEIZRAY
DOCETAXEL
1 shared
ZHUHAI
Shared indications:
Breast Cancer
BILDYOS
DENOSUMAB-NXXP
1 shared
SHANGHAI HENLIUS BIOTECH
Shared indications:
Breast Cancer
BONCRESA
DENOSUMAB-MOBZ
1 shared
AMNEAL PHARMS LLC
Shared indications:
Breast Cancer
BOSAYA
DENOSUMAB-KYQQ
1 shared
BIOCON BIOLOGICS INC
Shared indications:
Breast Cancer
CAPECITABINE
CAPECITABINE
1 shared
TEYRO LABS
Shared indications:
Breast Cancer
CERIANNA
FLUOROESTRADIOL F-18
1 shared
GE HEALTHCARE
Shared indications:
Breast Cancer
CONEXXENCE
DENOSUMAB-BNHT
1 shared
Fresenius Kabi
Shared indications:
Breast Cancer
CONJUGATED ESTROGENS
ESTROGENS, CONJUGATED
1 shared
NOVAST LABS
Shared indications:
Breast Cancer
DATROWAY
DATOPOTAMAB DERUXTECAN-DLNK
1 shared
DAIICHI SANKYO INC
Shared indications:
Breast Cancer
DOCIVYX
DOCETAXEL
1 shared
AVYXA HOLDINGS
Shared indications:
Breast Cancer
DOXIL (LIPOSOMAL)
DOXORUBICIN HYDROCHLORIDE
1 shared
Baxter
Shared indications:
Breast Cancer
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
DOXORUBICIN HYDROCHLORIDE
1 shared
AYANA PHARMA LTD
Shared indications:
Breast Cancer
ELLENCE
EPIRUBICIN HYDROCHLORIDE
1 shared
Pfizer
Shared indications:
Breast Cancer
ENOBY
DENOSUMAB-QBDE
1 shared
Hikma
Shared indications:
Breast Cancer
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ITOVEBI FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies ] . ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positiv...

ITOVEBI Patents & Exclusivity

Latest Patent: Jun 2038
Exclusivity: Oct 2029

Patents (28 active)

US12410189 Expires Jun 14, 2038
US11028100 Expires Apr 26, 2038
US11760753 Expires Jul 1, 2036
US9650393 Expires Jul 1, 2036
US10851091 Expires Jul 1, 2036
US8343955 Expires Sep 27, 2030
US8242104 Expires Sep 27, 2030
+ 18 more patents

Exclusivity

NCE Until Oct 2029
NCE Until Oct 2029
NCE Until Oct 2029
NCE Until Oct 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.